Financings Roundup

April 2008
BioWorld Today;4/10/2008, Vol. 19 Issue 70, p6
The article reports on a $12 million round of financing completed by Potentia Pharmaceuticals Inc. of Louisville, Kentucky. The fund will be used to complete the company's Phase I study of POT-4, a potential treatment for age-related macular degeneration, and move it into Phase II. The drug is a complement component C3 inhibitor.


Related Articles

  • Potentia Poises for Validation in Complement Inhibition in AMD. Morrison, Trista // BioWorld Today;9/12/2008, Vol. 19 Issue 178, p1 

    The article reports that Potentia Pharmaceuticals, Inc. hopes to confirm the validity of complement inhibition as an approach to treating age-related macular degeneration (AMD) when the result of its Phase 1 study on the genetic link between AMD and various complement factors arrives. Potentia...

  • Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.  // Nature Reviews Drug Discovery;Dec2009, Vol. 8 Issue 12, p922 

    The article reports on the agreement between Alcon Research and Potentia Pharmaceuticals Inc. to develop an inhibitor for the treatment of age-related macular degeneration (AMD) which is a major cause of blindness. Reportedly, Potentia's complement pathway inhibitor, POT-4 will be developed by...

  • Sight preserved in AMD patients receiving steroid derivative. Charters, Lynda // Ophthalmology Times;11/1/2003, Vol. 28 Issue 31, p59 

    Reports that findings from a phase II/III study conducted by the Anecortave Acetate Clinical Study Group indicate that anecortave acetate can have a positive impact on the treatment of patients with age-related macular degeneration (AMD). Long-term benefits that anecortave acetate can provide...

  • Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons. Morrison, Trista // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p1 

    The article reports on the 30 million U.S. dollar Series B financing secured by Ophtotech Corp. The financing round is designed to support the clinical trials of the company's age-related macular degeneration (AMD) drugs. Samir Patel, president and chief executive officer (CEO) of Ophthotech,...

  • TargeGen Advances AMD Program With $40M.  // Bioworld Week;7/23/2007, Vol. 15 Issue 30, p2 

    The article reports that TargeGen Inc. closed Series D financing round, which raised $40 million that will be used to fund the upcoming Phase II development of its lead program in the U.S. The company's lead program is an eye drop for treating macular degeneration and other back-of-the-eye...

  • Laser reduces drusen, improves vision in AMD patients. Merbs, Shannath; Olk, R. Joseph // Ophthalmology Times;11/01/99, Vol. 24 Issue 21, p54 

    Provides information on a pilot clinical trial conducted to assess the effectiveness and safety of infrared diode laser macular photocoagulation for non-exudative age-related macular degeneration (AMD). Outcome measures that have been studied; Results of the study.

  • Studies to determine if others may benefit from PDT. Talsma, Julia // Ophthalmology Times;2/15/2002, Vol. 27 Issue 4, p10 

    Highlights several clinical trials aimed at expanding the benefits of photodynamic therapy (PDT) for patients with subfoveal choroidal neovascularization (CNV) in age-related macular degeneration. Results of the PDT with verteporfin trial; Rationale of the Visudyne In Minimally Classic CNV...

  • CNV development in fellow eye more active after first year of anti-VEGF treatment. Mullin, David W.; Nale, Patricia // Primary Care Optometry News;Jul2012, Vol. 17 Issue 7, p9 

    The article reports on the claim by Doctor Maureen G. Maguire that based on a 2-year data, more fellow eyes of patients culled from the Complications of Age-Related Macular Degeneration Treatment Trials (CATT) developed choroidal neovascularization in the second year of follow-up than the first.

  • Update: Phase II study outcomes encouraging for treating exudative AMD with combination therapy. Guttman, Cheryl // Ophthalmology Times;11/15/2008, Vol. 33 Issue 22, p18 

    The article cites key findings from an 18-month phase II clinical trial in the U.S. indicating that the combination of epiretinal brachytherapy and bevacizumab is an effective and safe way to treat exudative age-related macular degeneration (AMD). The combination therapy also minimizes the need...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics